Composite PharmacoKinetics (PK) of Panobinostat and Bortezomib: AUClast, AUC0-24h, AUC0-48h, AUCinf
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2019-11-18
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
PK sample collection was performed in subjects who agreed to blood samplings for the PK assessments of PAN and BTZ. The order of administration of the 3 study treatment components was 1) PAN, 2) Dex, and 3) BTZ.
Analysis population: PAS: Pharmacokinetic Analysis Set (PAS): The PK analysis set for PAN (PAS-PAN) consisted of all subjects with at least one evaluable PK concentration of PAN. The PK analysis set for BTZ (PAS-BTZ) consisted of all subjects with at least one evaluable PK concentration of BTZ.
Groups in this outcome
LBH589 + Bortezomib + Dexamethasone
Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
8
Reported measurements
PAN: AUClast C1D1
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
8
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
106
14.7
Not reported
Not reported
Not reported
PAN: AUClast C1D8
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
7
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
156
31.7
Not reported
Not reported
Not reported
BJB432: AUClast C1D1
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
8
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
37.8
38.2
Not reported
Not reported
Not reported
BJB432: AUClast C1D8
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
7
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
166
87.7
Not reported
Not reported
Not reported
PAN: AUC0-24h C1D1
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
8
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
87.1
13.7
Not reported
Not reported
Not reported
PAN: AUC0-24h C1D8
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
7
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
125
30.1
Not reported
Not reported
Not reported
BJB432: AUC0-24h C1D1
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
8
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
18.5
33.9
Not reported
Not reported
Not reported
BJB432: AUC0-24h C1D8
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
7
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
83.8
76.1
Not reported
Not reported
Not reported
PAN: AUC0-48h C1D1
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
8
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
106
14.8
Not reported
Not reported
Not reported
PAN: AUC0-48h C1D8
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
7
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
156
31.7
Not reported
Not reported
Not reported
BJB432: AUC0-48h C1D1
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
7
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
36.8
40.6
Not reported
Not reported
Not reported
BJB432: AUC0-48h C1D8
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
6
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
169
98.8
Not reported
Not reported
Not reported
PAN: AUCinf C1D1
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
8
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
116
15.5
Not reported
Not reported
Not reported
PAN: AUCinf C1D8
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
7
Values in h.ng/mL · Interval/dispersion: Geometric Coefficient of Variation
Group
Value
Spread
Lower
Upper
Comment
LBH589 + Bortezomib + Dexamethasone
175
32.7
Not reported
Not reported
Not reported
BJB432: AUCinf C1D1
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
0
BJB432: AUCinf C1D8
Analysis denominator · Participants
Group
Source count
LBH589 + Bortezomib + Dexamethasone
0
Complete source fields
classes
categories
measurements
group Id
OG000
spread
14.7
value
106
denoms
counts
group Id
OG000
value
8
units
Participants
title
PAN: AUClast C1D1
categories
measurements
group Id
OG000
spread
31.7
value
156
denoms
counts
group Id
OG000
value
7
units
Participants
title
PAN: AUClast C1D8
categories
measurements
group Id
OG000
spread
38.2
value
37.8
denoms
counts
group Id
OG000
value
8
units
Participants
title
BJB432: AUClast C1D1
categories
measurements
group Id
OG000
spread
87.7
value
166
denoms
counts
group Id
OG000
value
7
units
Participants
title
BJB432: AUClast C1D8
categories
measurements
group Id
OG000
spread
13.7
value
87.1
denoms
counts
group Id
OG000
value
8
units
Participants
title
PAN: AUC0-24h C1D1
categories
measurements
group Id
OG000
spread
30.1
value
125
denoms
counts
group Id
OG000
value
7
units
Participants
title
PAN: AUC0-24h C1D8
categories
measurements
group Id
OG000
spread
33.9
value
18.5
denoms
counts
group Id
OG000
value
8
units
Participants
title
BJB432: AUC0-24h C1D1
categories
measurements
group Id
OG000
spread
76.1
value
83.8
denoms
counts
group Id
OG000
value
7
units
Participants
title
BJB432: AUC0-24h C1D8
categories
measurements
group Id
OG000
spread
14.8
value
106
denoms
counts
group Id
OG000
value
8
units
Participants
title
PAN: AUC0-48h C1D1
categories
measurements
group Id
OG000
spread
31.7
value
156
denoms
counts
group Id
OG000
value
7
units
Participants
title
PAN: AUC0-48h C1D8
categories
measurements
group Id
OG000
spread
40.6
value
36.8
denoms
counts
group Id
OG000
value
7
units
Participants
title
BJB432: AUC0-48h C1D1
categories
measurements
group Id
OG000
spread
98.8
value
169
denoms
counts
group Id
OG000
value
6
units
Participants
title
BJB432: AUC0-48h C1D8
denoms
counts
group Id
OG000
value
8
units
Participants
description
PK sample collection was performed in subjects who agreed to blood samplings for the PK assessments of PAN and BTZ. The order of administration of the 3 study treatment components was 1) PAN, 2) Dex, and 3) BTZ.
dispersion Type
Geometric Coefficient of Variation
groups
description
Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.
id
OG000
title
LBH589 + Bortezomib + Dexamethasone
param Type
GEOMETRIC_MEAN
population Description
PAS: Pharmacokinetic Analysis Set (PAS): The PK analysis set for PAN (PAS-PAN) consisted of all subjects with at least one evaluable PK concentration of PAN. The PK analysis set for BTZ (PAS-BTZ) consisted of all subjects with at least one evaluable PK concentration of BTZ.